Navigation Links
Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
Date:4/9/2008

ion Center

Preclinical data providing new details on SNS-314's anti-tumor activity will be presented Wednesday, April 16, 2008. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors.

SNS-314 Poster Presentation

Wednesday, April 16, 2008

-- SNS-314, a potent inhibitor of Aurora kinases, has preclinical

anti-activity and induces apoptosis

Session: Heat Shock Protein Inhibitors, Aurora Kinase and other Mitotic

Inhibitors

Abstract #5648

8:00 a.m. - 12:00 p.m. Exhibit Hall B-F, San Diego Convention Center

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
2. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
3. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
6. Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at Working 2 Walk in Washington, DC, April 13-15, 2008
7. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
8. MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
9. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
10. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
11. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... BRIDGEWATER, N.J. , Sept. 16, 2014 /PRNewswire/ ... pharmaceutical company focused on developing and commercializing therapeutic ... renal and infectious diseases, announces the amendment and ... and E preferred stock and related warrants, as ... 2014 common stock and warrant financing, to remove ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/15/2014)... , Sept. 16, 2014 The French ... (HNF) announced today an agreement to collaborate on programs ... support the development of a stronger CMT patient and ... support to several HNF,s initiatives including: , ... the HNF website featuring  HNF newsletters, materials and latest ...
Breaking Medicine Technology:CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 2Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 3Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease 4
(Date:9/16/2014)... Tara Haelle ... News) -- About 14.5 million U.S. cancer survivors are ... the American Association for Cancer Research reported Tuesday. ... and include nearly 380,000 survivors of childhood cancer, according ... advances in prevention, identification, research and treatment of cancer ...
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... ) filed against C.R. Bard, Inc. continue to ... in U.S. District Court, Southern District of West ... Order dated September 15, 2014, the Court has ... beneficial to the proceeding. The Order indicates that ...
(Date:9/16/2014)... Danny Dreyer, ChiRunning & ChiWalking founder ... events throughout the U.S. Dreyer is one of the ... taught a full circuit of nationwide workshops since 2004. ... tracks at his workshops so participants of all levels ... techniques. , Workshop schedule: , ,     September ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... The Wistar Institute,s Meenhard Herlyn, D.V.M., D.Sc., is ... Program of Research Excellence (SPORE) grant, a prestigious ... researchers at Wistar and the University of Pennsylvania ... this SPORE is to translate fundamental laboratory discoveries ... melanoma and other skin cancers. , Melanoma is ...
Breaking Medicine News(10 mins):Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 3
... disturbing implications for the government, pension companies and life ... warning that increases in longevity translate into bad news ... look after us when we are old; to make ... uncertain. , Kevin Dowd, Professor of Financial Risk Management ...
... 29th 2007 With the genomic revolution radical improvement ... cancer. This is of the utmost importance, since the ... detection. In a special issue of Disease Markers, published ... the identification and understanding of biomarkers for epithelial ovarian ...
... found incidentally during a CT scan, and the masses ... according to a recent study conducted by researchers at ... increased utilization of CT, we are frequently encountering findings ... scanned, the so called incidentalomas, of which adrenal masses ...
... winning program at the Best Practices in Consumer ... 25-26, 2008, WASHINGTON, Nov. 29 Today ... selected the finalists for its,inaugural Best Practices in ... attracted entries detailing,innovative and proven programs that are ...
... Revolutionary new intimacy creme aids women in greater ... Passion Parties, Inc. is excited to,add the new ... cornerstone of the Passion Parties product line complete ... the G-Spot Creme instills a,positive level of confident ...
... Signs contract with Best Medical International Inc., ... leading,provider of medical isotopes and radiopharmaceuticals, today signed ... its external beam,therapy and self-contained irradiator product lines. ... growth strategy to focus its resources on being ...
Cached Medicine News:Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 2Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 3Health News:Passion Parties Hits the Spot 2Health News:MDS Nordion Divests Non Strategic Product Lines 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: